Skip to main content
. Author manuscript; available in PMC: 2014 Nov 24.
Published in final edited form as: J Mol Neurosci. 2012 Nov 16;49(2):250–261. doi: 10.1007/s12031-012-9917-z

Fig. 6.

Fig. 6

Analysis of c-myc and cyclin D1 expressions in NOD-MSCs. a Western blot analysis of c-myc and cyclin D1 expressions. β-Actin was used as the internal control. b Quantification of cyclin D1 protein levels. c Quantification of c-myc protein levels. After BDNF, NGF, and bFGF treatment for 7 and 14 days, c-myc and cyclin D1 protein levels were significantly decreased in NOD-MSCs compared with the ICR-MSCs (#P<0.05; n=5). d Western blot analysis of c-myc and cyclin D1 expressions after treatment with Wnt1 (10–400 ng/ml). e Quantification of c-myc and cyclin D1 protein levels after treatment with Wnt1 (10–400 ng/ml). Wnt1 concentrations >100 ng/mL were sufficient to increase c-myc and cyclin D1 expressions in NOD-MSCs (#P<0.05, $P<0.05; n=5)